An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Study Identifier
UBR-MD-04
CT.gov Identifier
NCT02873221
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Migraine - General
    • Study Drug
  • Ubrogepant
  • Placebo-matching Ubrogepant
  • Usual Care
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 76 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).
    Exclusion Criteria:
    * Patients with clinically significant electrocardiogram (ECG), vital sign, physical exam, or laboratory abnormalities * Requirement for a medication during the study that is on the list of prohibited medications.

    Protocol Summary

    This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

    Study Locations

    Location
    Status
    Location
    Clinsearch, LLC
    Chattanooga, Tennessee, United States, 37421
    8.5 miles (13.6 km) away from your location
    Status
    Not applicable